Peer Review History

Original SubmissionJuly 24, 2023
Decision Letter - Terna Ignatius Nomhwange, Editor

PONE-D-23-21989Geographic information system and information visualization: past successes and future challenges in capacity building for the World Health Organization’s African regionPLOS ONE

Dear Dr. Kipterer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 17 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Terna Ignatius Nomhwange, MD,DTM&H,MBA

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. We note that Figures 1 to 3 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

(1) You may seek permission from the original copyright holder of Figures 1 to 3 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

(2) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Additional Editor Comments:

  • Please review and consider all the comments and suggestions by both reviewers to provide more clarity and context within the manuscript.
  • Both reviewers have also highlighted the focus on Polio in the current draft and the need to revise the title and text to reflect the aim of this review as stated in Lines 92-95? Is the manuscript about GIS and Polio alone or other diseases as well? You may revise the title of the manuscript accordingly showing "past" Polio Successes." and challenges "post covid" for GIS utilization for other disease outbreaks. Any examples of how the GIS system has supported any other diseases? (how is the AFRO GIS Centre addressing these ongoing public health needs?)
  • The current title also includes "capacity building". The conclusion is specific for Polio and GPEI, is this capacity building for WHO GIS Polio teams or for country field staff for Polio and other diseases as well?
  • In line with the recommendation on the title, please update the abstract and the conclusion to ensure alignments. Note also that the conclusion only mentions Polio and nothing about other diseases outbreaks.
  • Lines 169-171 documents polio vaccination by WHO AFRO GIS teams? Does the AFRO GIS deploy vaccination teams or is this by the teams recruited by the Governments? Is there a reference for this?
  • The section on use of GIS beyond Polio (Lines 245-276) is a clear example of Polio transition in action. Please include a line or two on Polio transition.
  • Please also revise to correct sentences and punctuations as may be required for consistency E.g.:  Line 215 & 21: Train (Orient) participants "on" while Line 219: Train participants "in".

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In summary this manuscript outlines the development and expansion of the use of GIS systems in the African WHO region for primarily polio eradication. This is a very important technological development both for polio eradication and future disease surveillance and intervention monitoring. The manuscript provides narrative of the progress to date, highlighting particular GIS gaps (i.e. it is not a scientific research article). However, to a reader not involved in this GIS network, more details are required to understand the processes. The authors also present data from a 2019 survey on national GID capacity but more details are required as to who was surveyed and whether follow-up data will be collected to measure progress. It would be much clearer if different visualisations were presented for a particular outbreak that the network has worked on e.g., The authors conclude the GIS system was important for achieving certification of WPV1 in the region, it would be helpful to see some examples of the different GIS layers that contributed to this.

Minor comments:

Abstract:

‘Currently, 95% of reported polio cases are in under-vaccinated populations’ it is not clear what you mean by this given many children will not have received type 2 OPV since 2016.

Introduction

Line 49, I think you mean WPV1 free?

Line 66, By vaccine-associated do you mean vaccine-derived?

Fig 1 why do you choose this specific time period?

The introduction would benefit with a few sentences describing withdrawal of type 2 from OPV in 2016 and the following declining immunity across the region, facilitating cVDPV2 spread. A little more detail required on the rollout of nOPV2 would help the reader.

Figure 2 – Requires more details in the legend – how is the data obtained? Which part of Nigeria is shown?

Paragraph 114 – ‘Components of the WHO AFRO geographic information system’. This section is hard to follow. Perhaps include a diagram to show if any of these platforms interact? More description required to understand what ISS, eSurv and AVADAR are – how do they interact with other GIS platforms? Perhaps show an example from each? It would be helpful to highlight in the diagram what new spatial data is the GIS Centre helping to collect compared to visualising standard surveillance data. It is not clear what PowerBI is used for and what ARC GIS is used for.

Figure 3– what data is going into this dashboard? How are nomadic populations ‘tracked’ it could be interpreted as unethical tracking of certain people so please explain.

Figure 4 – what is the y axis? % missing or having. Please provide more details on the survey – questions in the appendix? Who participated?

Train the trainer – who are these trainers, how are they located across countries? Who are those being trained?

Line 232 – population and demographic data – based on what data source? Most recent census or other?

Line 262 Consolidated health facility master list – this is a very exciting development. Is it possible to report on how complete this database is? What are the barriers to obtaining more data etc? What proportion of countries have supplied data….

IPV – has the GIS Centre been involved in evaluating the (few) IPV campaigns?

Reviewer #2: Authors should align the title, the main text and the conclusion and recommendations of this paper. The paper in its current form seems to be too much focused on polio even though its intention is to highlight the application ion WHO AFRO GIS tool in prevention and control of not only polio but other diseases.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: PLOS ONE GIS.docx
Revision 1

Response to Reviewer/Editor Comments

PONE-D-23-21989

Geographic information system and information visualization: past successes and future challenges in capacity building for the World Health Organization’s African region

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Done.

2. Thank you for stating the following financial disclosure:

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: Please add the following text re the role of the funder: “The Bill & Melinda Gates Foundation provided human resource support during the trainings. Both funders were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.”

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Funding Statement should read as follows: “Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and the Bill & Melinda Gates Foundation. Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation.”

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: This has already been shared and data were downloaded: https://whonghub.org/faroukh/92/1537#/table (Username: faroukh; Password: Welcome12345). Text has been updated. [Lines 371-4]

5. We note that Figures 1 to 3 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

(1) You may seek permission from the original copyright holder of Figures 1 to 3 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

(2) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Response: Figure 1 has been revised and does not require permission. Sources for Figures 1 and 4 have been added to legends. New Figures 2 and 5 (formerly 3) are derived from GeoPoDe, an open-source, public data repository for geospatial reference datasets, and does not require permission. However, we have requested and received permission to be safe. (Note: GeoPoDe is a public web data repository for geospatial datasets available by country. The platform allows public health officials and partner organizations to visualise geospatial data on an interactive map and download the data in multiple formats. All datasets contained in GeoPode are available to non-profit or humanitarian applications and are “operational” in nature. The datasets do not constitute authoritative, government-sanctioned reference data.)

Additional Editor Comments:

• Please review and consider all the comments and suggestions by both reviewers to provide more clarity and context within the manuscript.

Response: Done

• Both reviewers have also highlighted the focus on Polio in the current draft and the need to revise the title and text to reflect the aim of this review as stated in Lines 92-95? Is the manuscript about GIS and Polio alone or other diseases as well? You may revise the title of the manuscript accordingly showing "past" Polio Successes." and challenges "post covid" for GIS utilization for other disease outbreaks. Any examples of how the GIS system has supported any other diseases? (how is the AFRO GIS Centre addressing these ongoing public health needs?)

Response: The title has been revised: “Geographic information system and information visualization capacity building: successful polio eradication, and current and future challenges in the COVID-19 era.”

Examples of GIS applications in routine immunization to improve vaccination coverage in the Lake Chad region,and many WHO/AFRO countries are enumerated in an earlier publication: Akpan GU et al. Conclusions of the African Regional GIS Summit (2019): using geographic information systems for public health decision-making. BMC Proc 16 (Suppl 1), 3 (2022). https://doi.org/10.1186/s12919-022-00233-y.

• The current title also includes "capacity building". The conclusion is specific for Polio and GPEI, is this capacity building for WHO GIS Polio teams or for country field staff for Polio and other diseases as well?

Response: Capacity building is for polio and other diseases, as well. As noted, title has been revised.

• In line with the recommendation on the title, please update the abstract and the conclusion to ensure alignments. Note also that the conclusion only mentions Polio and nothing about other diseases outbreaks.

Response: We have revised the last sentence in the abstract (“It also examines current and prospective challenges regarding other disease outbreaks in the COVID-19 era and how the AFRO GIS Centre is addressing these ongoing public health needs.”) to address this issue [Lines 42-3]. The end of the Conclusion has been revised: “…with the goal of faster detection and response to polio and other disease outbreaks in the COVID-19 era.” [Line 363]

• Lines 169-171 documents polio vaccination by WHO AFRO GIS teams? Does the AFRO GIS deploy vaccination teams or is this by the teams recruited by the Governments? Is there a reference for this?

Response: It is the role of WHO/AFRO to respond through vaccination, and deployment is jointly made by WHO and the respective government. Additional references have been added. https://www.afro.who.int/health-topics/polio/polio-update-on-country-situations/nigeria-and-the-lake-chad-countries; https://polioeradication.org/countries/lake-chad-region/

• The section on use of GIS beyond Polio (Lines 245-276) is a clear example of Polio transition in action. Please include a line or two on Polio transition.

Response: We have added the following text: “The integration of polio transition processes involves the bringing together of various stakeholders and resources to ensure a smooth and effective transition. This includes integrating polio surveillance systems into existing disease surveillance networks, incorporating polio vaccinations into routine immunization programs, and merging the expertise and infrastructure developed for polio eradication with broader public health initiatives.” [Lines 291-5]

• Please also revise to correct sentences and punctuations as may be required for consistency E.g.: Line 215 & 21: Train (Orient) participants "on" while Line 219: Train participants "in".

[Note: HTML markup is below. Please do not edit.]

Response: Done

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Response: Revisions made as specified in comments.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Response: N/A

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thanks

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thanks

Reviewer #1: In summary this manuscript outlines the development and expansion of the use of GIS systems in the African WHO region for primarily polio eradication. This is a very important technological development both for polio eradication and future disease surveillance and intervention monitoring. The manuscript provides narrative of the progress to date, highlighting particular GIS gaps (i.e. it is not a scientific research article). However, to a reader not involved in this GIS network, more details are required to understand the processes. The authors also present data from a 2019 survey on national GID capacity but more details are required as to who was surveyed and whether follow-up data will be collected to measure progress. It would be much clearer if different visualizations were presented for a particular outbreak that the network has worked on e.g., The authors conclude the GIS system was important for achieving certification of WPV1 in the region, it would be helpful to see some examples of the different GIS layers that contributed to this.

Response: There are no layers involved; it was achieved through surveillance visits, with evidence of visits at the health facility level with GPS enabled on submission of visit checklists. The use of GIS enables technologies in vaccination tracking systems and the use of the AVADAR electronic surveillance checklist serves as evidence (see: https://doi.org/10.29245/2578-3009/2021/S2.1101, http://dx.doi.org/10.16966/2471-8211.151, doi: 10.11604/pamj.supp.2022.42.1.33788, 10.2196/18950), https://doi.org/10.1186/s12889-018-6187-x).

Minor comments:

Abstract:

‘Currently, 95% of reported polio cases are

Attachments
Attachment
Submitted filename: Kipterer PLOS1 Response 022824.docx
Decision Letter - Terna Ignatius Nomhwange, Editor

Geographic information system and information visualization capacity building: successful polio eradication and current and future challenges in the COVID-19 era for the World Health Organization’s African region

PONE-D-23-21989R1

Dear Mr.Kipterer

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Terna Ignatius Nomhwange, MD,DTM&H,MBA

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Terna Ignatius Nomhwange, Editor

PONE-D-23-21989R1

PLOS ONE

Dear Dr. Kipterer,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Terna Ignatius Nomhwange

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .